Docket No.: 62386-015

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Wayne D. COMPER

Serial No.: 09/893,346

Filed: June 28, 2001

Group Art Unit: 1648

Examiner: not yet assigned

METHOD FOR KIDNEY DISEASE TREATMENT BY DRUG INTERVENTION

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents Washington, DC 20231

TECH CENTER 1600/2900

Sir:

For:

Attached is a copy of the Filing Receipt received from the U.S. Patent and Trademark Office in the above-referenced application. It is noted that the Applicant information is incorrectly recorded. Attached is a copy of the Declaration filed on September 18, 2001, which evidences that the Applicant information should read -- WAYNE D. COMPER, VICTORIA, AUSTRALIA--. It is requested that a corrected filing receipt be issued.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Registration No. 22,685

600 13th Street, N.W. Washington, DC 20005-3096 (202)756-8000 RLP:lrb Facsimile: (202)756-8087

Date: July 26, 2002





UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

IND CLAIMS FIL FEE REC'D ATTY.DOCKET.NO **DRAWINGS** APPLICATION NUMBER FILING DATE GRP ART UNIT **TOT CLAIMS** 858 48643-015 17 21 1648 09/893,346 06/28/2001

CONFIRMATION NO. 2638

MCDERMOTT, WILL & EMERY 600 13th Street, N.W. Washington, DC 20005-3096

UPDATED FILING RECEIPT OC000000006937920*

Date Mailed: 10/19/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Wayne D. Comper, Victoria, AUSTRIA;

AUSTRALIA

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/415,217 10/12/1999

S. ANG.

NEV 27 am

COEMMOTT, WILL & ENER

Foreign Applications

AUSTRALIA PP7843 12/21/1998 PCT/IB99/02029 12/20/1999

If Required, Foreign Filing License Granted 07/17/2001

Projected Publication Date: 01/31/2002

Non-Publication Request: No

Early Publication Request: No

Title

Method for kidney disease treatment by drug intervention

Preliminary Class

435



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).